MIB-1 Immunoreactivity Correlates with Blood Vessel Density and Survival in Disseminated Malignant Melanoma
- 1 October 1999
- journal article
- Published by S. Karger AG in Oncology
- Vol. 57 (3) , 242-252
- https://doi.org/10.1159/000012038
Abstract
The purpose of our current work was to evaluate the prognostic significance of tumor cell proliferation in advanced metastatic melanomas and to investigate a possible correlation between the proliferation index and blood vessel density in metastatic tissue. Sixty patients with disseminated malignant melanoma treated with four-drug chemotherapy combined with interferon-α were included in this study. Proliferative activity and vascularity in metastatic tissues were examined by immunohistochemistry with anti-Ki-67 (MIB-1) and anti-CD31 antibody, respectively. A significant relationship between MIB-1 index and blood vessel number was detected (rho = 0.323, p = 0.013). In survival analysis, the overall survival and disease-free survival were significantly longer (58 and 38 vs. 38 and 17 months) for patients with low MIB-1 immunoreactivity (p = 0.012 and p = 0.023, respectively). Likewise, the low MIB-1 labeling index was associated with the prolonged survival calculated from the initiation of the chemoimmunotherapy (12 vs. 7 months, p = 0.032). In multivariate Cox’s proportional hazard analysis, MIB-1 positivity was an independent prognostic factor both for overall survival and for survival after beginning of the chemoimmunotherapy (p = 0.016 and p = 0.029).Keywords
This publication has 4 references indexed in Scilit:
- Tumor Vascularity, Proliferation, and Apoptosis in Human Melanoma Micrometastases and MacrometastasesArchives of Dermatology, 1998
- Prognostic Significance Of MIB-1 Proliferative Activity in Thin Melanomas and Immunohistochemical Analysis of MIB-1 Proliferative Activity in Melanocytic TumorsThe American Journal of Dermatopathology, 1998
- Vascularity and prognosis of metastatic melanomaInternational Journal of Cancer, 1997
- Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanomaInternational Journal of Cancer, 1996